DC
ACRS icon

Diametric Capital’s Aclaris Therapeutics ACRS Stock Holding History

Diametric Capital’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-30,137
Closed -$46.1K – 318
2025
Q1 		$46.1K Buy
+30,137
New +$64.3K 0.05% 192
2021
Q2 		– Sell
-11,038
Closed -$278K – 134
2021
Q1 		$278K Buy
+11,038
New +$216K 0.21% 100

Other funds holding ACRS

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Diametric Capital's ACRS Position: Q2 2025 in Review

Diametric Capital sold out of Aclaris Therapeutics (ACRS) in Q2 2025, closing a stake of 30,137 shares — an estimated $46.1K sold.

Diametric Capital first reported a position in ACRS in Q1 2021 and held it in 2 quarters. The position peaked at $278K in Q1 2021. 96 funds tracked by Wall St. Rank hold ACRS as of Q2 2025.

  • Diametric Capital reported no remaining Aclaris Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Diametric Capital sold 30,137 Aclaris Therapeutics shares in Q2 2025, an estimated $46.1K.
  • Diametric Capital first reported a position in Aclaris Therapeutics in Q1 2021 and held it in 2 quarters.
  • Diametric Capital's Aclaris Therapeutics position peaked at $278K in Q1 2021.
  • 96 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q2 2025.

Based on Diametric Capital's 13F filing for Q2 2025, filed 13 Aug 2025.